Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

Marcin Kowanetz, Wei Zou, David S. Shames et al. · Annals of Oncology · 2016

Cited by 48 works. doi:10.1093/annonc/mdw363.25 Open-access PDF

Authors